sub:provenance {
  beldoc: dce:description "Approximately 61,000 statements." ;
    dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved." ;
    dce:title "BEL Framework Large Corpus Document" ;
    pav:authoredBy sub:_5 ;
    pav:version "1.4" .
  sub:_4 prov:value "Table 1 Small molecule inhibitors of ErbB tyrosine kinases in clinical development EGFR IC50 HER2 IC50 HER4 IC50 Agent (umol/l) (umol/l) (umol/l) Reversible/irreversible Source Gefitinib (Iressa, ZD1839) 0.02 3.7 NR Reversible AstraZeneca Erlotinib (Tarceva, OSI-774) 0.02 3.5 NR Reversible Genentech/Roche EKB-569 0.038 1.2 NR Irreversible Wyeth-Ayerst TAK-165 NR 0.006 NR NR Takeda GW572016 0.011 0.009 NR Reversible GlaxoSmithKline PKI-166 0.02 0.1 NR Reversible Novartis AEE-788 0.002 0.006 0.16 Reversible Novartis CI-1033 0.0008 0.019 0.007 Irreversible Pfizer AEE-788 also inhibits KDR with a 50% inhibitory concentration (IC50) of 0.077 umol/l. NR, not reported. EGFR, epidermal growth factor receptor; HER, human epidermal growth factor receptor." ;
    prov:wasQuotedFrom pubmed:15318926 .
  sub:_5 rdfs:label "Selventa" .
  sub:assertion prov:hadPrimarySource pubmed:15318926 ;
    prov:wasDerivedFrom beldoc: , sub:_4 .
}